Pfizer lung cancer drug crizotinib has great potential for the treatment of "lobular" breast cancer

Pfizer lung cancer drug crizotinib has great potential for the treatment of "lobular" breast cancer

April 04, 2018 Source: Sina Pharmaceutical

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Recently, a recent study by scientists at the British Cancer Institute (ICR) found that Xalkori (crizotinib, crizotinib), an anticancer drug commonly used in the treatment of non-small cell lung cancer (NSCLC), kills specific genetic defects. Breast cancer cells. This major discovery is expected to provide a new targeted therapy for thousands of breast cancer patients.

In this study, scientists at the ICR Toby Robbins Research Center confirmed that crizotinib attacks the weakness of breast cancer cells through a mechanism called "synthetic lethal", making it useful for the treatment of lobular breast cancer (LBC). . Currently, ICR and the Royal Marsden NHS Trust have launched an important Phase II clinical study, ROLO, to investigate the potential of crizotinib for the treatment of advanced LBC.

"Velcro" defect targeting cancer cells

In the study, scientists found that crizotinib is particularly effective against cancer cells with genetic defects in E-cadherin. Calpain-E is a calcium-dependent transmembrane protein that is involved in cell-cell adhesion and is distributed in various epithelial cells of humans and animals. It plays an important role in maintaining cell polarity and integrity. effect. In normal cells, this protein acts like a "nylon buckle" to help cells bind together. Cadherin-E genetic defects are common in cancer cells and can lead to abnormal growth and division of cancer cells.

It is estimated that more than 13% of all breast cancer cases have cadherin-E deficiency, and the incidence in lobular breast cancer is as high as 90%. In addition, cadherin-E deficiency is also present in some cases of triple negative breast cancer (TNBC).

About 7150 women in the UK are diagnosed with breast cancer with a genetic defect of cadherin-E each year. However, there are currently no specific treatments for this type of breast cancer, and few people know what weaknesses are present in such cancer cells.

New breakthrough research

In this study, published in Cancer Discovery, a team of ICR scientists, Dr. Chris Lord and Dr. Ilirjana Bajrami, tested 80 small molecule inhibitors to see if certain drugs in these drugs can cause calcium adhesion. Protein-E genetically deficient cancer cells die.

The study explored a method of targeting tumors, called "synthesis-killing," which takes advantage of two key genes on which cancer cells depend. If one of the two genes does not function properly due to mutations, then Blocking another gene with a drug produces a lethal killing effect that leads to the death of cancer cells.

Working with King's College London and Dutch scientists, the team found that crizotinib showed the most significant synthetic lethal effect. Crizotinib is marketed by Pfizer, a class of ROS1 inhibitor drugs. The researchers found that crizotinib kills cadherin-E-deficient breast cancer cells, while normal cells are relatively unaffected.

This finding confirms that by inhibiting the cell surface receptor ROS1, a new path will be opened to target the treatment of cadherin-E cancer types with genetic defects.

Overcoming drug resistance

Lobular breast cancer is usually driven by estrogen (oestrogen), so hormone therapy is the main treatment for this type of patient. However, drug resistance is common, and lobular breast cancer does not respond well to chemotherapy. This means that such patients have few treatment options if they progress after receiving current hormonal therapy.

Cell and mouse tests in the laboratory found that the lethal effects of crizotinib and other ROS1 inhibitors also play a role in the endocrine resistance model, suggesting that these drugs can be used for patients who have developed hormone resistance. Provide important treatment options.

Based on this major finding, Phase II ROLO studies have initiated and tested the efficacy of crizotinib in patients with cadherin-E deficiency, ER-positive, and advanced lobular breast cancer. The study is currently the only study in the world that specializes in new treatments for advanced lobular breast cancer.

The second drug that targets "synthetic lethal"

If the efficacy can be demonstrated in clinical studies, this major finding is expected to lead to the second targeted breast cancer drug that uses the "synthetic lethal" mechanism following the PARP inhibitor olaparib. Olapani was discovered by British scientists at the ICR in 2005. It can target two breast cancer genes, BRCA1 and BRCA2, with genetic defects. In January 2018, the drug was approved by the US FDA for HER2 negative advanced breast cancer with BRCA mutations. Currently, Olapani has been introduced to the market by AstraZeneca under the brand name Lynparza. It is reported that this is also the first time PARP inhibitors have been approved for the treatment of breast cancer.

Given that cadherin-E deficiency is one of the most common genetic alterations found in all human cancers, ROS1 inhibitors such as crizotinib are expected to be effective in the treatment of a variety of other cancers, including gastric cancer. (Sina Pharmaceutical Compilation/newborn)

Article reference source: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer

Cane & Walker

Walking aids is an auxiliary device to assist the human body to support weight, maintain balance and walk. It can also be called walking aids, walking stands or walking aids. Among walking aids, walking aids can provide the greatest support and stability. Therefore, it is mainly used for patients with weak strength and poor balance, such as the elderly after orthopedic surgery, patients with poor coordination and Parkinson's disease, and children with cerebral palsy or developmental retardation. With the support of equipment, people with less flexible legs can walk and take care of themselves.
According to the structure and function of Walker, it can be divided into two categories: stick walker and frame walker. The walking aid is simple and light in structure, but its supporting area is small and its stability is poor; The frame walker has a complex structure, but it has a large supporting area and good stability.
Before using the walker, the user's physical condition and use environment should be comprehensively evaluated, including balance ability, lower limb bearing ability, gait, upper limb ability, cognitive ability, lifestyle and use environment.
Select a walker
1. The texture should be light and easy for patients to move.
2. The walker should be placed stably on the ground;
3. The height of the walker should be suitable or adjustable. When the patient stands in the walker and his hands are naturally sagging, he can hold the handrails on both sides and apply pressure on the handrails to ensure the support of weight and balance control;
4. The width of the walker should be moderate, not too wide.

TRUTECH CO., LTD. is an enterprise specializing in the research, development, production and sales of professional OTC products.The main products include shower chairs, armrests, toilet racks and toilet armrests, bedside armrests, elderly chairs and sofas, crutches and walking aids, knee pads, waist supports and other equipment.

Cane & Walker,Canes And Walkers,Cane Walker,Walking Stick

TRUTECH CO., LTD. , https://www.trutechealth.com